David Fitz-Patrick, MD
Endocrinology · Honolulu, HINPI 1275531154
Payments from drug & device makers
Across 2,193 payments — averaging $12,027 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$16.2M
- Modernatx, Inc.$4.7M
- Eli Lilly$1.9M
- Novo Nordisk AS$939K
- AstraZeneca$755K
- Amgen$540K
- plus $1.4M from 21 others
Across 31 payments — averaging $8476.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- BD$194K
- Eli Lilly$31K
- Pfizer$29K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Amryt Pharma Holdings Ltd$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 616 | $16,207,240 |
| Modernatx, Inc. | 150 | $4,659,077 |
| Eli Lilly | 42 | $1,874,256 |
| Novo Nordisk AS | 947 | $938,883 |
| AstraZeneca | 19 | $754,724 |
| Amgen | 8 | $540,435 |
| Regeneron | 64 | $485,132 |
| Boehringer Ingelheim | 21 | $282,961 |
| Bayer | 114 | $213,360 |
| CSL Behring | 47 | $100,127 |
| AbbVie(2 entities) | 37 | $90,684 |
| Gilead | 22 | $63,035 |
| Sanofi US Services Inc. | 10 | $40,887 |
| Novartis | 2 | $37,370 |
| Boehringer Ingelheim International GmbH | 74 | $22,597 |
| Astrazeneca UK Limited | 3 | $21,543 |
| BD | 2 | $20,911 |
| Madrigal Pharmaceuticals | 1 | $4,794 |
| Lexicon Pharmaceuticals, Inc. | 1 | $3,955 |
| Shire North American Group Inc | 2 | $3,800 |
| Chiasma, Inc. | 2 | $3,775 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $3,325 |
| Chiesi USA, Inc. | 1 | $1,081 |
| Amryt Pharma Holdings Ltd | 1 | $611 |
| Dexcom, Inc. | 2 | $30 |
| Medline Industries LP | 1 | $28 |
| Abbott | 1 | $15 |
How this compares
Too few endocrinology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology in Honolulu
- Michael BornemannHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.